|
1
|
The impact of carbapenemases on antimicrobial development and therapy.
|
2002
|
2.41
|
|
2
|
Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
|
2007
|
1.95
|
|
3
|
PI3K pathway-directed therapeutic strategies in cancer.
|
2010
|
1.85
|
|
4
|
Sirtuins: novel targets for metabolic disease.
|
2008
|
1.80
|
|
5
|
Autophagy inhibition in combination cancer treatment.
|
2009
|
1.79
|
|
6
|
Artemisinins for schistosomiasis and beyond.
|
2007
|
1.77
|
|
7
|
The endocannabinoid system: a drug discovery perspective.
|
2005
|
1.75
|
|
8
|
Candida biofilms: antifungal resistance and emerging therapeutic options.
|
2004
|
1.69
|
|
9
|
Angiogenesis, neurogenesis and brain recovery of function following injury.
|
2010
|
1.67
|
|
10
|
B-Raf kinase inhibitors for cancer treatment.
|
2007
|
1.67
|
|
11
|
Diamidines as antitrypanosomal, antileishmanial and antimalarial agents.
|
2006
|
1.64
|
|
12
|
MicroRNAs: small but potent oncogenes or tumor suppressors.
|
2006
|
1.63
|
|
13
|
Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.
|
2009
|
1.57
|
|
14
|
Cardiovascular effects of insulin sensitizers in diabetes.
|
2006
|
1.55
|
|
15
|
Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
|
2002
|
1.52
|
|
16
|
Neuroimmune interactions and pain: focus on glial-modulating targets.
|
2008
|
1.50
|
|
17
|
Autoimmunity in autism.
|
2009
|
1.49
|
|
18
|
Neurobiological mechanisms of addiction: focus on corticotropin-releasing factor.
|
2010
|
1.49
|
|
19
|
Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
|
2008
|
1.46
|
|
20
|
Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancer.
|
2009
|
1.46
|
|
21
|
Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics.
|
2009
|
1.43
|
|
22
|
Diamidines for human African trypanosomiasis.
|
2010
|
1.42
|
|
23
|
RAGE in inflammation: a new therapeutic target?
|
2006
|
1.40
|
|
24
|
The role of IL-17 and family members in the pathogenesis of arthritis.
|
2003
|
1.40
|
|
25
|
A review of HCV protease inhibitors.
|
2009
|
1.39
|
|
26
|
Experimental therapeutics: targeting the redox Achilles heel of cancer.
|
2007
|
1.38
|
|
27
|
PKCtheta: A potential therapeutic target for T-cell-mediated diseases.
|
2006
|
1.37
|
|
28
|
The IL-17/IL-23 axis of inflammation in cancer: friend or foe?
|
2009
|
1.36
|
|
29
|
Multimodal analgesia: its role in preventing postoperative pain.
|
2008
|
1.36
|
|
30
|
PPARbeta/delta ligands as modulators of the inflammatory response.
|
2008
|
1.36
|
|
31
|
Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
|
2005
|
1.34
|
|
32
|
TLR4 antagonists for endotoxemia and beyond.
|
2005
|
1.34
|
|
33
|
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
|
2010
|
1.34
|
|
34
|
Fatty acid biosynthesis as a target for novel antibacterials.
|
2004
|
1.33
|
|
35
|
Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer.
|
2005
|
1.31
|
|
36
|
S-1360 Shionogi-GlaxoSmithKline.
|
2003
|
1.31
|
|
37
|
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
|
2006
|
1.30
|
|
38
|
Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.
|
2001
|
1.29
|
|
39
|
The pleuromutilin antibiotics: a new class for human use.
|
2010
|
1.29
|
|
40
|
Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
|
2010
|
1.28
|
|
41
|
Alpha v integrin inhibitors and cancer therapy.
|
2003
|
1.28
|
|
42
|
Mitogen-activated protein kinases as potential targets for pain killers.
|
2004
|
1.27
|
|
43
|
Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway.
|
2004
|
1.27
|
|
44
|
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
|
2010
|
1.27
|
|
45
|
Prospects for the development of novel anti-hyperlipidemic drugs.
|
2006
|
1.27
|
|
46
|
GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
|
2009
|
1.26
|
|
47
|
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
|
2008
|
1.25
|
|
48
|
Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.
|
2008
|
1.25
|
|
49
|
Isoprenoid biosynthesis as a novel target for antibacterial and antiparasitic drugs.
|
2004
|
1.25
|
|
50
|
Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis.
|
2007
|
1.24
|